Kos Pharmaceuticals, Inc.

Kos Pharmaceuticals, Inc. develops and proprietary pharmaceutical products for the treatment of chronic cardiovascular, metabolic, and respiratory diseases. Its products include niaspan for treatment of mixed lipid disorders; advicor for treatment of primary hypercholesterolemia and mixed dyslipidemia in patients treated with component lipid modification for low-density lipoproteins (LDL) and high-density lipoproteins (HDL) cholesterol, and triglycerides; and azmacort product, an inhaled corticosteroid that alleviates inflammation in lungs and used as prophylactic therapy for the treatment of asthma. The company’s products also include cardizem LA, a non-dihydropyridine calcium channel blocker for the treatment of hypertension and chronic stable angina; teveten, an angiotensin II receptor blocker for the treatment of hypertension; and teveten HCT, an anti-hypertensive agent combines teveten and a diuretic for blood pressure control. In addition, it offers solid-dose drug delivery systems and metered-dose inhalation devices, and other device products, as well as conducts research on respiratory and inhalation delivery. The company was founded in 1988 and is based in Cranbury, New Jersey. Kos Pharmaceuticals, Inc. operates as a subsidiary of AbbVie Inc.